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Background: The value of central event adjudication of endpoints in multi-center randomized trials has recently been questioned.
Methods: The NIH-sponsored Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial randomized 4,060 atrial fibrillation 
patients to antiarrhythmic drugs (rhythm control) vs. rate-controlling drugs, given open-label, at 213 clinical sites. While the primary outcome was 
mortality, a key secondary endpoint was ischemic stroke (IS), centrally adjudicated by those reviewing source documents from which data regarding 
rate/rhythm treatment was purged.
Results: 190 cases of first IS were submitted by local investigators, and 141 (74%) were confirmed after adjudication. More submitted IS were 
excluded in the rhythm control arm (30 of 101, 30%) vs. the rate control arm (19 of 89, 21%), p=.19. The relative risk reduction in IS by rate control 
using unadjudicated events was 12% vs. 1% using adjudicated events. Based on IS confirmed by adjudication, there was no evidence of a treatment 
difference (HR=1.04, p=0.79). While examining first IS regardless of adjudication also did not provide evidence of a treatment difference, the hazard 
ratio was appreciably increased (HR=1.15) and the p-value decreased (p=0.33).
Conclusions: 1. There is evidence for biased reporting of IS by unblinded local investigators. 2. Using first adjudicated IS or first reported IS results 
in different estimates of event rates and treatment effects that are clinically relevant. 3. Central blinded event adjudication importantly altered the 
key IS outcome in the AFFIRM trial.
